Cognitive decline across five cognitive batteries: Sample size implications for clinical trials.

ABSTRACT:

Introduction

We evaluated the statistical power for a theoretical randomized trial of anti-amyloid treatment in preclinical Alzheimer's Disease across five cognitive composites in preclinical Alzheimer's Disease across five cognitive composites: Alzheimer's Prevention Initiative Preclinical Composite Cognitive Test (APCC); Preclinical Alzheimer's Composite with Semantic Processing (PACC5); Preclinical Alzheimer's Cognitive Composite (PACC); and global and episodic memory composites.

Methods

We utilized annual cognitive assessments from 517 decedents (78.2 ± 4.7years; 72% female) with post mortem pathologic Alzheimer's disease (AD) to represent amyloid positivity. We calculated sample sizes to detect 30% reduction in 5-year slopes of cognitive decline for equal size tr

SUBMITTER: Zammit AR 

PROVIDER: S-EPMC12265016 | biostudies-literature | 2025 Jul-Sep

REPOSITORIES: biostudies-literature